Literature DB >> 20156780

Gastrointestinal stromal tumours at present: an approach to burning questions.

Manuel García de Polavieja Carrasco1, Ana de Juan Ferré, Marta Mayorga Fernández.   

Abstract

Because of their well known origin in gene mutations and a revolutionary therapy by means of molecular targets, gastrointestinal stromal tumours (GIST) constitute a plentiful and paradigmatic model of translational investigation, resulting in an avalanche of exponential growth data. In this article, we focus on what we consider to be hot spots in GIST at present. A wide spectrum of events is approached, extending from subtle pathogenic mechanisms at a molecular level (gene mutations and their implications for cell receptors with subsequent activation of signalling pathways) to more practical problems facing diagnosis (molecular markers, role of biopsy), prognosis (risk stratification systems) and different therapeutic aspects (laparoscopic surgery, role of surgery in advanced disease, response criteria, adjuvant and neoadjuvant therapy, treatment for progressing and recurrent disease, therapy directed on mutation analysis and new developments, among others). The review has been endorsed by level of evidence evaluation through a recognised pattern to assist in teaching, and a final summary of recommendations and a management algorithm are included.

Entities:  

Mesh:

Year:  2010        PMID: 20156780     DOI: 10.1007/S12094-010-0476-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  107 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

Review 2.  Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.

Authors:  Peter Reichardt; Pancras C W Hogendoorn; Elena Tamborini; Massimo Loda; Alessandro Gronchi; Andrés Poveda; Patrick Schöffski
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

3.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

4.  Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study.

Authors:  Regine Schneider-Stock; Carsten Boltze; Jerzy Lasota; Brigitte Peters; Chris L Corless; Petra Ruemmele; Luigi Terracciano; Matthias Pross; Luigi Insabato; Dolores Di Vizio; Igor Iesalnieks; Stefan Dirnhofer; Arndt Hartmann; Michel Heinrich; Markku Miettinen; Albert Roessner; Luigi Tornillo
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors.

Authors:  Atsushi Motegi; Shinji Sakurai; Hiroko Nakayama; Takaaki Sano; Tetsunari Oyama; Takashi Nakajima
Journal:  Pathol Int       Date:  2005-03       Impact factor: 2.534

6.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

7.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

8.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

9.  Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

Authors:  Jean-Yves Blay; Axel Le Cesne; Isabelle Ray-Coquard; Binh Bui; Florence Duffaud; Catherine Delbaldo; Antoine Adenis; Patrice Viens; Maria Rios; Emmanuelle Bompas; Didier Cupissol; Cecile Guillemet; Pierre Kerbrat; Jérome Fayette; Sylvie Chabaud; Patrice Berthaud; David Perol
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

10.  Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Authors:  N Widmer; L A Decosterd; S Leyvraz; M A Duchosal; A Rosselet; M Debiec-Rychter; C Csajka; J Biollaz; T Buclin
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640

View more
  1 in total

1.  The Purple Clinical Series: a useful tool for clinical oncologists to tackle current hot spots in cancer.

Authors: 
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.